Harnessing Synergy: Multi-Modal Approaches to Enhance CAR T-Cell Therapy in Multiple Myeloma
Time: 12:10 pm
day: Day One
Details:
• CAR-T cell therapy in multiple myeloma is currently not curative; an exhausted and immunosuppressive microenvironment contributes to resistance and relapse
• Immunomodulatory agents activate T and NK cells as monotherapy and could be used to extend responses with limited downside
• Multimodal treatment strategy can be applied to T cell-engaging therapies more broadly
